Raymond G. Perelman Center for Cellular and Molecular Therapeutics team highlights that extended safety testing of AAV-based RNAi strategies is critical.
Transforming the diagnosis, management, and treatment of traumatic brain injury (TBI) with new tools for TBI assessment that will change the paradigm of medical care at the individual, community, and population levels.
